145 related articles for article (PubMed ID: 27508184)
1. Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models.
Braidwood L; Learmonth K; Graham A; Conner J
J Hepatocell Carcinoma; 2014; 1():149-61. PubMed ID: 27508184
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
Sorensen A; Mairs RJ; Braidwood L; Joyce C; Conner J; Pimlott S; Brown M; Boyd M
J Nucl Med; 2012 Apr; 53(4):647-54. PubMed ID: 22414636
[TBL] [Abstract][Full Text] [Related]
3. Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy.
Conner J; Braidwood L
Cancer Gene Ther; 2012 Jul; 19(7):499-507. PubMed ID: 22595793
[TBL] [Abstract][Full Text] [Related]
4. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
Quigg M; Mairs RJ; Brown SM; Harland J; Dunn P; Rampling R; Livingstone A; Wilson L; Boyd M
Med Chem; 2005 Sep; 1(5):423-9. PubMed ID: 16787326
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
Mace AT; Harrow SJ; Ganly I; Brown SM
Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients.
Streby KA; Geller JI; Currier MA; Warren PS; Racadio JM; Towbin AJ; Vaughan MR; Triplet M; Ott-Napier K; Dishman DJ; Backus LR; Stockman B; Brunner M; Simpson K; Spavin R; Conner J; Cripe TP
Clin Cancer Res; 2017 Jul; 23(14):3566-3574. PubMed ID: 28495911
[No Abstract] [Full Text] [Related]
7. Oncolytic herpesvirus therapy for mesothelioma - A phase I/IIa trial of intrapleural administration of HSV1716.
Danson SJ; Conner J; Edwards JG; Blyth KG; Fisher PM; Muthana M; Salawu A; Taylor F; Hodgkinson E; Joyce P; Roman J; Simpson K; Graham A; Learmonth K; Woll PJ
Lung Cancer; 2020 Dec; 150():145-151. PubMed ID: 33160198
[TBL] [Abstract][Full Text] [Related]
8. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma.
Mace AT; Ganly I; Soutar DS; Brown SM
Head Neck; 2008 Aug; 30(8):1045-51. PubMed ID: 18615711
[TBL] [Abstract][Full Text] [Related]
9. Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours.
Detta A; Harland J; Hanif I; Brown SM; Cruickshank G
J Gene Med; 2003 Aug; 5(8):681-9. PubMed ID: 12898637
[TBL] [Abstract][Full Text] [Related]
10. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.
Harrow S; Papanastassiou V; Harland J; Mabbs R; Petty R; Fraser M; Hadley D; Patterson J; Brown SM; Rampling R
Gene Ther; 2004 Nov; 11(22):1648-58. PubMed ID: 15334111
[TBL] [Abstract][Full Text] [Related]
11. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
Conner J; Braidwood L; Brown SM
Gene Ther; 2008 Dec; 15(24):1579-92. PubMed ID: 18701918
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion.
Cockle JV; Brüning-Richardson A; Scott KJ; Thompson J; Kottke T; Morrison E; Ismail A; Carcaboso AM; Rose A; Selby P; Conner J; Picton S; Short S; Vile R; Melcher A; Ilett E
Mol Ther Oncolytics; 2017 Jun; 5():75-86. PubMed ID: 28547002
[TBL] [Abstract][Full Text] [Related]
13. HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib
Tazzyman S; Stewart GR; Yeomans J; Linford A; Lath D; Conner J; Muthana M; Chantry AD; Lawson MA
Viruses; 2023 Feb; 15(3):. PubMed ID: 36992311
[TBL] [Abstract][Full Text] [Related]
14. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.
Papanastassiou V; Rampling R; Fraser M; Petty R; Hadley D; Nicoll J; Harland J; Mabbs R; Brown M
Gene Ther; 2002 Mar; 9(6):398-406. PubMed ID: 11960316
[TBL] [Abstract][Full Text] [Related]
15. TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma.
Hutzen B; Chen CY; Wang PY; Sprague L; Swain HM; Love J; Conner J; Boon L; Cripe TP
Mol Ther Oncolytics; 2017 Dec; 7():17-26. PubMed ID: 29034312
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus.
Wong RJ; Kim SH; Joe JK; Shah JP; Johnson PA; Fong Y
J Am Coll Surg; 2001 Jul; 193(1):12-21. PubMed ID: 11442249
[TBL] [Abstract][Full Text] [Related]
17. HSV1716 persistence in primary human glioma cells in vitro.
Harland J; Papanastassiou V; Brown SM
Gene Ther; 2002 Sep; 9(17):1194-8. PubMed ID: 12170384
[TBL] [Abstract][Full Text] [Related]
18. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma.
MacKie RM; Stewart B; Brown SM
Lancet; 2001 Feb; 357(9255):525-6. PubMed ID: 11229673
[TBL] [Abstract][Full Text] [Related]
19. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.
Advani SJ; Buckel L; Chen NG; Scanderbeg DJ; Geissinger U; Zhang Q; Yu YA; Aguilar RJ; Mundt AJ; Szalay AA
Clin Cancer Res; 2012 May; 18(9):2579-90. PubMed ID: 22379115
[TBL] [Abstract][Full Text] [Related]
20. Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability.
Howard F; Conner J; Danson S; Muthana M
Front Mol Biosci; 2022; 9():889395. PubMed ID: 35782876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
